Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 20, 2021updated 07 Jan 2022 7:18am

Russia’s Sputnik V vaccine shows effectiveness against Omicron variant

When administered as a booster, Sputnik Light induced neutralising antibodies against Omicron in all individuals.

The Russian Direct Investment Fund (RDIF) has reported that the Covid-19 vaccine Sputnik V and the single-dose Sputnik Light booster vaccine demonstrated effectiveness against the Omicron variant of the SARS-CoV-2 virus in a study.

Carried out by the Gamaleya Center in Russia, the laboratory study found that both the vaccines demonstrated greater virus neutralising activity (VNA) against Omicron and could potentially offer a robust defence against severe Covid-19 and hospital admission.

As against other available vaccines, Sputnik V showed a three to seven times decline in virus neutralising activity against Omicron.

Data showed that Sputnik V provided 11.8 times decline in VNA versus 41 and 49-84 times reduction for Covid-19 vaccines of Pfizer-BioNTech and Moderna, respectively.

Sputnik V induced a robust and durable T-cell response while the mutations in the Omicron variant did not impact 80% of epitopes in the spike protein.

Furthermore, heterologous boosting with Sputnik Light was demonstrated to improve the efficacy of vaccines, even against Omicron and offered extended booster protection duration.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Data showed that Sputnik Light administered as a booster caused a substantial surge in virus neutralising activity against Omicron two to three months after revaccination.

In mix and match trials carried out in Argentina, Sputnik Light when administered in combination with AstraZeneca, Sinopharm, Moderna and Cansino’s vaccines demonstrated to elicit robust antibody and T-cell response versus homologous vaccine regimen.

In addition, each vaccine cocktail provided a greater antibody titer on the 14th day following the second shot versus the vaccination homogenous shots.

A combination of AstraZeneca’s vaccine plus Sputnik Light demonstrated strong neutralising antibodies growth in a trial in the Republic of Azerbaijan, RDIF reported in September this year.

Currently, Sputnik Light is registered in over 20 countries as a standalone vaccine as well as a universal booster to other shots.

Both Sputnik V and Sputnik Light are not linked to rare serious adverse events including myocarditis or pericarditis.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU